Synthesis of N-Methylene Linker Containing Phthalimide Bearing-1H-1,2,3-Triazole by Click Chemistry Approach: Anticancer Activity in Human Cells

References

• S.P. Phatak, R.D. Bakale, S.T. Dhumal, L.K. Dahiwade, P.B. Choudhari, V.S. Krishna, D. Sriram, and K.P. Haval, “Synthesis, Antitubercular Evaluation and Molecular Docking Studies of Phthalimide Bearing 1,2,3-Triazoles,” Synthetic Communications 49, no. 16 (2019): 2017–28. doi:10.1080/00397911.2019.1614630.
   Web of Science ®Google Scholar
• H.C. Kolb, M.G. Finn, and K.B. Sharpless, “Click Chemistry: Diverse Chemical Function from a Few Good Reactions,” Angewandte Chemie International Edition 40, no. 11 (2001): 2004–21. doi:10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5.
   PubMed Web of Science ®Google Scholar
• J. Bai, Y. Li, and G. Zhang, “Cell Cycle Regulation and Anticancer Drug Discovery,” Cancer Biology & Medicine 14, no. 4 (2017): 348–62.
   PubMed Web of Science ®Google Scholar
• J.A. Ayukekbong, M. Ntemgwa, and A.N. Atabe, “The Threat of Anti-Microbial Resistance in Developing Countries: Causes and Control Strategies,” Antimicrobial Resistance and Infection Control 6 (2017): 47. doi:10.1186/s13756-017-0208-x.
   PubMed Web of Science ®Google Scholar
• A. Sahu, P. Sahu, and R. Agrawal, “Synthesis, Pharmacological and Toxicological Screening of Penicillin–Triazole Conjugates (PNTCs),” ACS Omega 4, no. 17 (2019): 17230–5. doi:10.1021/acsomega.9b01724.
   PubMed Web of Science ®Google Scholar
• P.S. Auti, G. George, and A.T. Paul, “Recent Advances in the Pharmacological Diversification of Quinazoline/Quinazolinone Hybrids,” RSC Advances 10, no. 68 (2020): 41353–92. doi:10.1039/D0RA06642G.
   PubMed Web of Science ®Google Scholar
• L. Tietze, B. Hubertus, and S. Chandrasekhar, “Natural Product Hybrids as New Leads for Drug Discovery,” Angewandte Chemie (International ed. in English) 42, no. 34 (2003): 3996–4028. doi:10.1002/anie.200200553.
   PubMed Web of Science ®Google Scholar
• A. Sahu, R.K. Agrawal, and R. Pandey, “Synthesis and Systemic Toxicity Assessment of Quinine-Triazole Scaffold with Antiprotozoal Potency,” Bioorganic Chemistry 88 (2019): 102939. doi:10.1016/j.bioorg.2019.102939.
   PubMed Web of Science ®Google Scholar
• C. Deraedt, N. Pinaud, and D. Astruc, “Recyclable Catalytic Dendrimer Nanoreactor for Part-Per-Million Cu(I) Catalysis of Click Chemistry in Water,” Journal of the American Chemical Society 136, no. 34 (2014): 12092–8. doi:10.1021/ja5061388.
   PubMed Web of Science ®Google Scholar
• C. Barner-Kowollik, F.E.D. Prez, P. Espeel, C.J. Hawker, T. Junkers, H. Schlaad, and W.V. Camp, “Clicking” Polymers or Just Efficient Linking: What is the Difference,” Angewandte Chemie (International ed. in English) 50, no. 1 (2011): 60–2. doi:10.1002/anie.201003707.
   PubMed Web of Science ®Google Scholar
• J.E. Hein, and V.V. Fokin, “Copper-Catalyzed Azide-Alkyne Cycloaddition (CuAAC) and beyond: New Reactivity of Copper(i) Acetylides,” Chemical Society Reviews 39, no. 4 (2010): 1302–15. doi:10.1039/b904091a.
   PubMed Web of Science ®Google Scholar
• V.V. Rostovtsev, L.G. Green, V.V. Fokin, and K.B. Sharpless, “A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” pf Azides and Terminal Alkynes,” Journal of the Chemical Society Chemical Communication 114, no. 14 (2002): 2708–11.
   Google Scholar
• Q. Wang, T.R. Chan, R. Hilgraf, V.V. Fokin, K.B. Sharpless, and M.G. Finn, “Bioconjugation by Copper(I)-Catalyzed Azide-Alkyne [3 + 2] Cycloaddition,” Journal of the American Chemical Society 125, no. 11 (2003): 3192–3. doi:10.1021/ja021381e.
   PubMed Web of Science ®Google Scholar
• A.E. Speers, G.C. Adam, and B.F. Cravatt, “Activity-Based Protein Profiling In Vivo Using a Copper(I)-Catalyzed Azide-Alkyne [3 + 2] Cycloaddition,” Journal of the American Chemical Society 125, no. 16 (2003): 4686–7. doi:10.1021/ja034490h.
   PubMed Web of Science ®Google Scholar
• Z.L. He, H.L. Teng, and C.J. Wang, “Fulvenes as Effective Dipolarophiles in Copper(I)-Catalyzed [6 + 3] Cycloaddition of Azomethine Ylides: Asymmetric Construction of Piperidine Derivatives,” Angewandte Chemie (International ed. in English) 52, no. 10 (2013): 2934–8. doi:10.1002/anie.201208799.
   PubMed Web of Science ®Google Scholar
• X. Bian, Q. Wang, C. Ke, G. Zhao, and Y. Li, “A New Series of N-2-Substituted-5-(p-Toluenesulfonylamino) Phthalimide Analogues as a-Glucosidase Inhibitors,” Bioorganic & Medicinal Chemistry Letters 23, no. 7 (2013): 2022–6. doi:10.1016/j.bmcl.2013.02.011.
   PubMed Web of Science ®Google Scholar
• Miguel A. González, Julie Clark, Michele Connelly, and Fatima Rivas, “Antimalarial Activity of Abietane Ferruginol Analogues Possessing a Phthalimide Group,” Bioorganic & Medicinal Chemistry Letters 24, no. 22 (2014): 5234–7. doi:10.1016/j.bmcl.2014.09.061.
   PubMed Web of Science ®Google Scholar
• Alexandre Légora Machado, Lídia Moreira Lima, João Xavier Araújo, Carlos Alberto M. Fraga, Vera Lúcia Gonçalves Koatz, and Eliezer J. Barreiro, “Design, Synthesis and Antiinflammatory Activity of Novel Phthalimide Derivatives, Structurally Related to Thalidomide,” Bioorganic & Medicinal Chemistry Letters 15, no. 4 (2005): 1169–72. doi:10.1016/j.bmcl.2004.12.012.
   PubMed Web of Science ®Google Scholar
• Phoebe F. Lamie, John N. Phillopes, Ahmed O. El-Gendy, Lucie Rarova, and Jiri Gruz, “Design, Synthesis and Evaluation of Novel Phthalimide Derivatives as In Vitro Anti-Microbial, Anti-Oxidant and Anti-Inflammatory Agents,” Molecules 20, no. 9 (2015): 16620–42. doi:10.3390/molecules200916620.
   PubMed Web of Science ®Google Scholar
• S. Nagarajan, S. Majumder, U. Sharma, S. Rajendran, N. Kumar, S. Chatterjee, and B. Singh, “Synthesis and Anti-Angiogenic Activity of Benzothiazole, Benzimidazole Containing Phthalimide Derivatives,” Bioorganic & Medicinal Chemistry Letters 23, no. 1 (2013): 287–90. doi:10.1016/j.bmcl.2012.10.106.
   PubMed Web of Science ®Google Scholar
• H. Akgun, I. Karameleko, B. Berk, I. Kurnaz, G. Sarıbıyık, S. Oktem, and T. Kocag€Oz, “Synthesis and Antimycobacterial Activity of Some Phthalimide Derivatives,” Bioorganic & Medicinal Chemistry 20, no. 13 (2012): 4149–54. doi:10.1016/j.bmc.2012.04.060.
   PubMed Web of Science ®Google Scholar
• A. Rani, A. Viljoen, L. Kremer, and V. Kumar, “Microwave-Assisted Highly Efficient Route to 4-Aminoquinoline-Phthalimide Conjugates: Synthesis and Anti-Tubercular Evaluation,” Chemistry Select 2, no. 33 (2017): 10782–5. doi:10.1002/slct.201702220.
   Google Scholar
• J.L. Santos, P.R. Yamasaki, C.M. Chin, C.H. Takashi, F.R. Pavan, and C.Q. Leite, “Synthesis and in Vitro anti Mycobacterium tuberculosis Activity of a Series of Phthalimide Derivatives,” Bioorganic & Medicinal Chemistry 17, no. 11 (2009): 3795–9. doi:10.1016/j.bmc.2009.04.042.
   PubMed Web of Science ®Google Scholar
• N. Kushwaha, A. Tripathi, and S.K.S. Kushwaha, “Synthesis, Characterization and In Vitro Anti Mycobacterium tuberculosis Evaluation of Some Novel Phthalimide Derivatives,” Der Pharma Chemical 6 (2014): 188–96.
   Google Scholar
• D. Ashok, P. Chiranjeevi, A.V. Kumar, M. Sarasija, V.S. Krishna, D. Sriram, and S. Balasubramanian, “1,2,3-Triazole-Fused Spirochromenes as Potential Anti-Tubercular Agents: Synthesis and Biological Evaluation,” RSC Advances 8, no. 30 (2018): 16997–7007. doi:10.1039/C8RA03197E.
   PubMed Web of Science ®Google Scholar
• F. Gao, H. Yang, T. Lu, Z. Chen, L. Ma, Z. Xu, P. Schaffer, and G. Lu, “Design, Synthesis and anti-Mycobacterial Activity Evaluation of Benzofuran-Isatin Hybrids,” European Journal of Medicinal Chemistry 159 (2018): 277–81. doi:10.1016/j.ejmech.2018.09.049.
   PubMed Web of Science ®Google Scholar
• R.J. Naik, M.V. Kulkarni, K.S.R. Pai, and P.G. Nayak, “Click Chemistry Approach for Bis-Chromenyl Triazole Hybrids and Their Antitubercular Activity,” Chemical Biology & Drug Design 80, no. 4 (2012): 516–23. doi:10.1111/j.1747-0285.2012.01441.x.
   PubMed Web of Science ®Google Scholar
• M.H. Shaikh, D.D. Subhedar, F.A.K. Khan, J.N. Sangshetti, L. Nawale, M. Arkile, D. Sarkar, and B.B. Shingate, “Synthesis of Novel Triazole-Incorporated Isatin Derivatives as Antifungal, Antitubercular, and Antioxidant Agents and Molecular Docking Study,” Journal of Heterocyclic Chemistry 54, no. 1 (2017): 413–21. doi:10.1002/jhet.2598.
   Web of Science ®Google Scholar
• Y. Sajja, S. Vanguru, H.R. Vulupala, R. Bantu, P. Yogeswari, D. Sriram, and L. Nagarapu, “Design, Synthesis and in Vitro anti-Tuberculosis Activity of Benzo [6,7] Cyclohepta[1,2-b] Pyridine-1,2,3-Triazole Derivatives,” Bioorganic & Medicinal Chemistry Letters 27, no. 23 (2017): 5119–21. doi:10.1016/j.bmcl.2017.10.071.
   PubMed Web of Science ®Google Scholar
• V.V. Rostovtsev, L.G. Green, V.V. Fokin, and K.B. Sharpless, “A Stepwise Huisgen Cycloaddition Process: Copper(I)-Catalyzed Regioselective “Ligation” of Azides and Terminal Alkynes,” Angewandte Chemie 114, no. 14 (2002): 2708–11. doi:10.1002/1521-3757(20020715)114:14<2708::AID-ANGE2708>3.0.CO;2-0.
   Google Scholar
• K. Kushwaha, N.L. Kaushik, and S.C. Jain, “Design and Synthesis of Novel 2H-Chromen-2- One Derivative Bearing 1,2,3-Triazole Moiety as Lead Antimicrobials,” Bioorganic & Medicinal Chemistry Letters 24, no. 7 (2014): 1795–801. doi:10.1016/j.bmcl.2014.02.027.
   PubMed Web of Science ®Google Scholar
• R. Gonzalez-Olvera, A. Espinoza-Vazquez, G. Negron-Silva, M. Palomar-Pardave, M. Romero-Romo, and R. Santillan, “Multicomponent Click Synthesis of New 1,2,3-Triazole Derivatives of Pyrimidine Nucleobases: Promising Acidic Corrosion Inhibitors for Steel,” Molecules 18, no. 12 (2013): 15064–79. doi:10.3390/molecules181215064.
   PubMed Web of Science ®Google Scholar
• L.T. Li, L.F. Zhou, Y.J. Li, J. Huang, R.H. Liu, B. Wang, and P. Wang, “Facile Synthesis of 1,2,3-Triazole Analogs of SGLT2 Inhibitors by ‘Click Chemistry,” Bioorganic & Medicinal Chemistry Letters 22, no. 1 (2012): 642–4. doi:10.1016/j.bmcl.2011.10.062.
   PubMed Web of Science ®Google Scholar
• Q. Sun, Y. Yao, C. Liu, H. Li, H. Yao, X. Xue, J. Liu, Z. Tu, and S. Jiang, “Design, Synthesis, and Biological Evaluation of Novel Histone Deacetylase 1 Inhibitors through Click Chemistry,” Bioorganic & Medicinal Chemistry Letters 23, no. 11 (2013): 3295–9. doi:10.1016/j.bmcl.2013.03.102.
   PubMed Web of Science ®Google Scholar
• G. Wang, Z. Peng, J. Wang, J. Li, and X. Li, “Synthesis and Biological Evaluation of Novel 2,4,5-Triarylimidazole-1,2,3-Triazole Derivatives via Click Chemistry as a-Glucosidase Inhibitors,” Bioorganic & Medicinal Chemistry Letters 26, no. 23 (2016): 5719–23. doi:10.1016/j.bmcl.2016.10.057.
   PubMed Web of Science ®Google Scholar
• A. Anand, M.V. Kulkarni, S.D. Joshi, and S.R. Dixit, “One-Pot Click Chemistry: A Three-Component Reaction for the Synthesis of 2-Mercaptobenzimidazole Linked Coumarinyl Triazoles as anti-Tubercular Agents,” Bioorganic & Medicinal Chemistry Letters 26, no. 19 (2016): 4709–13. doi:10.1016/j.bmcl.2016.08.045.
   PubMed Web of Science ®Google Scholar
• S.D. Hadiyal, N.D. Parmar, P.L. Kalavadiya, J.N. Lalpara, and H.S. Joshi, “Microwave-Assisted Three-Component Domino Synthesis of Polysubstituted 4H-Pyran Derivatives and Their Anticancer Activity,” Russian Journal of Organic Chemistry 56, no. 4 (2020): 671–8. doi:10.1134/S1070428020040168.
   Web of Science ®Google Scholar
• A.J. Radia, J.N. Lalpara, I.J. Modasiya, and G.G. Dubal, “Design and Synthesis of Novel 1,3,4‐Oxadiazole Based Azaspirocycles Catalyzed by NaI under Mild Condition and Evaluated Their Antidiabetic and Antibacterial Activities,” Journal of Heterocyclic Chemistry 58, no. 2 (2021): 612–21. doi:10.1002/jhet.4200.
   Web of Science ®Google Scholar
• Navneet P. Mori, Priti K. Parmar, Vijay M. Khedker, Gaurav Sanghavi, and Ranjan C. Khunt, “Synthesis and Characterization of Some New Alkyne Containing Thiazole Derivatives as a Docking Study,” Asian Journal of Organic & Medicinal Chemistry 6, no. 2 (2021): 92–101. doi:10.14233/ajomc.2021.AJOMC-P319.
   Google Scholar
• P.K. Parmar, N.P. Mori, V.M. Khedkar, G. Sanghavi, and R.C. Khunt, “Synthesis, Characterization & Molecular Docking Study of Hydrazinylthiazole Derivatives as Antibacterial Agents,” Analytical Chemistry Letters 12, no. 2 (2022): 244–54. doi:10.1080/22297928.2021.1983873.
   Google Scholar
• S.L. Holbeck, R. Camalier, J.A. Crowell, J.A. Govindharajulu, M. Hollingshead, L.W. Anderson, E. Polley, L. Rubinstein, A. Srivastava, D. Wilsker, et al., “The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity,” Cancer Research 77, no. 13 (2017): 3564–76. doi:10.1158/0008-5472.CAN-17-0489.
   PubMed Web of Science ®Google Scholar
• Mathilde R. Desselle, Ruth Neale, Karl A. Hansford, Johannes Zuegg, Alysha G. Elliott, Matthew A. Cooper, and Mark At Blaskovich, “Institutional Profile: Community for Open Antimicrobial Drug Discovery-Crowdsourcing New Antibiotics and Antifungals,” Future Science OA 3, no. 2 (2017): FSO171. doi:10.4155/fsoa-2016-0093.
   PubMedGoogle Scholar
• N. Jackson, L. Czaplewski, and L.V. Piddock, “Discovery and Development of New Antibacterial Drugs: learning from Experience,” The Journal of Antimicrobial Chemotherapy 73, no. 6 (2018): 1452–9. doi:10.1093/jac/dky019.
   PubMed Web of Science ®Google Scholar
• “Discovery & Development Services | DTP,” can be found under https://dtp.cancer.gov/discoverydevelopment/nci-60/handling.htm
   Google Scholar
• M.R. Boyd and K.D. Paull, “Some Practical Considerations and Applications of the National Cancer Institute in Vitro Anticancer Drug Discovery Screen,” Drug Development Research 34, no. 2 (1995): 91–109. doi:10.1002/ddr.430340203.
   Web of Science ®Google Scholar
• K. Ranal, A. Arora, S. Bansal, and R. Chawla, “Synthesis, In Vitro Anticancer and Antimicrobial Evaluation of Novel Substituted Dihydropyridines,” Indian Journal of Pharmaceutical 76, no. 4 (2014): 339.
   Google Scholar
• Ghaneya S. Hassan, Gehan H. Hegazy, Noha M. Ibrahim, and Samar H. Fahim, “New Ibuprofen Derivatives as H2S and NO Donors as Safer anti-Inflammatory Agents,” Future Medicinal Chemistry 11, no. 23 (2019): 3029–52. doi:10.4155/fmc-2018-0467.
   PubMed Web of Science ®Google Scholar
• B. Morak-Młodawska, K. Pluta, M. Latocha, M. Jelen, and D. KúSmierz, “Design, Synthesis, and Structural Characterization of Novel Diazaphenothiazines with 1,2,3-Triazole Substituents as Promising Antiproliferative Agents,” Molecules 24, no. 23 (2019): 4388–99. doi:10.3390/molecules24234388.
   PubMed Web of Science ®Google Scholar
• Artur Beberok, Dorota Wrześniok, Jakub Rok, Zuzanna Rzepka, Michalina Respondek, and Ewa Buszman, “Ciprofloxacin Triggers the Apoptosis of Human Triple-Negative Breast Cancer MDA-MB-231 Cells via the p53/Bax/Bcl-2 Signaling Pathway,” International Journal of Oncology 52, no. 5 (2018): 1727–37. doi:10.3892/ijo.2018.4310.
   PubMed Web of Science ®Google Scholar
• R.A. Friesner, J.L. Banks, R.B. Murphy, T.A. Halgren, J.J. Klicic, D.T. Mainz, M.P. Repasky, E.H. Knoll, M. Shelley, J.K. Perry, et al., “A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy,” Journal of Medicinal Chemistry 47, no. 7 (2004): 1739–49. doi:10.1021/jm0306430.
   PubMed Web of Science ®Google Scholar
• T.A. Halgren, R.B. Murphy, R.A. Friesner, H.S. Beard, L.L. Frye, W.T. Pollard, and J.L. Banks, “A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening,” Journal of Medicinal Chemistry 47, no. 7 (2004): 1750–9. doi:10.1021/jm030644s.
   PubMed Web of Science ®Google Scholar
• J. Akhtar, A.A. Khan, Z. Ali, R. Haider, and S.M. Yar, “Structure-Activity Relationship (SAR) Study and Design Strategies of Nitrogen-Containing Heterocyclic Moieties for Their Anticancer Activities,” European Journal of Medicinal Chemistry 125 (2017): 143–89. doi:10.1016/j.ejmech.2016.09.023.
   PubMed Web of Science ®Google Scholar
• B. Banerji, K. Chandrasekhar, K. Sreenath, S. Roy, S. Nag, and D. Saha, “Synthesis of Triazole-Substituted Quinazoline Hybrids for Anticancer Activity and a Lead Compound as the EGFR Blocker and ROS Inducer Agent,” ACS Omega 3, no. 11 (2018): 16134–42. doi:10.1021/acsomega.8b01960.
   PubMed Web of Science ®Google Scholar
• H. Zhou and Y. Wang, “Recent Researches in Triazole Compounds as Medicinal Drugs,” Current Medicinal Chemistry 19, no. 2 (2012): 239–80. doi:10.2174/092986712803414213.
   PubMed Web of Science ®Google Scholar
• S. Ivanov, V.F. Traven, and M.E. Minyaev, “Structural Studies of 3-Tert-Butyl-8-(Methylchalcogenyl) Pyrazolo[5,1-c] [1,2,4] Triazin-4(1H)-Ones,” Structural Chemistry 31, no. 4 (2020): 1457–70. doi:10.1007/s11224-020-01533-9.
   Web of Science ®Google Scholar